Lab-Grown tumor clones could pick best drugs for liver cancer patients
NCT ID NCT07363356
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether growing a patient's tumor cells in the lab (as organoids) can help doctors choose the most effective drugs after liver cancer surgery. 56 adults with high-risk features will have their tumor tested against several approved drugs. The goal is to see if this personalized approach improves how long patients stay cancer-free compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Organoid drug sensitivity testing to guide choice of Apatinib, Atezolizumab+Bevacizumab, Donafenib+Toripalimab, Sintilimab, or FOLFOX
What this could lead to
If successful, this approach could personalize cancer treatment after liver surgery, potentially reducing the chance of the cancer coming back.
What could go wrong
This is a small, early-phase trial (56 people) at one hospital. The organoid test may fail or not accurately predict which drug works best, and some drugs have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Third Affiliated Hospital of Naval Medical University, Shanghai, Shanghai 200433/201805
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••